Physician profile
David Falco
NPI 1639106016
$2,920.71
in general payments reported to CMS, 2019-2025
24 companies · $35.87 in 2025
The $35.87 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $724 · 2021: $704 · 2022: $701 · 2023: $38.10 · 2025: $35.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $73.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $73.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $623.55 | 2019-2022 | |
| Glaxosmithkline, LLC. | $331.30 | 2020-2025 | Shingrix |
| Astrazeneca Pharmaceuticals Lp | $303.49 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $299.48 | 2019-2022 | |
| Abbvie INC. | $231.04 | 2021-2022 | |
| Amarin Pharma, INC. | $221.45 | 2019-2021 | |
| Pfizer INC. | $206.09 | 2019-2022 | |
| Lilly USA, LLC | $157.29 | 2019-2022 | |
| Abbott Laboratories | $107.40 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $79.37 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.74 | 2019-2022 | |
| Daiichi Sankyo INC. | $56.32 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $43.67 | 2021-2022 | |
| Exact Sciences Corporation | $38.10 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $26.40 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $24.28 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $20.39 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $14.93 | 2022 | |
| Opko Pharmaceuticals, LLC | $14.04 | 2022 | |
| Genentech USA, INC. | $13.86 | 2022 | |
| Ibsa Pharma INC. | $12.88 | 2020 | |
| Xeris Pharmaceuticals, INC. | $12.78 | 2022 | |
| Ironwood Pharmaceuticals, INC | $12.77 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Falco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.